Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model. The Dow Jones Industrial Average ( ^DJI) is trading up 170 points (+1.3%) at 13,282 as of Tuesday, Nov 6, 2012, 1:34 p.m. ET. During this time, 312.7 million shares of the 30 Dow components have changed hands vs. an average daily trading volume of 573.4 million. The NYSE advances/declines ratio sits at 2,147 issues advancing vs. 786 declining with 122 unchanged.
EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.
The Dow component leading the way higher looks to be E.I. du Pont de Nemours & Company (NYSE: DD), which is sporting a 34-cent gain (+0.8%) bringing the stock to $44.67. This single gain is lifting the Dow Jones Industrial Average by 2.57 points or roughly accounting for 1.5% of the Dow's overall gain. Volume for E.I. du Pont de Nemours & Company currently sits at 3.3 million shares traded vs. an average daily trading volume of 5.3 million shares. E.I. du Pont de Nemours & Company has a market cap of $41.17 billion and is part of the basic materials sector and chemicals industry. Shares are down 3.6% year to date as of Monday's close. The stock's dividend yield sits at 3.9%. E. I. du Pont de Nemours and Company operates as a science and technology based company worldwide. Its Agriculture segment provides hybrid corn and soybean seeds, and grains under the Pioneer brand name; and herbicides, fungicides, and insecticides. The company has a P/E ratio of 13.5, below the S&P 500 P/E ratio of 17.7. TheStreet Ratings rates E.I. du Pont de Nemours & Company as a buy. Among the primary strengths of the company is its respectable return on equity which we feel is likely to continue. We feel these strengths outweigh the fact that the company has had sub par growth in net income.